BASF preparing squeeze-out process for Pronova, achieves 97.7% of shares
date:Jan 22, 2013
cids, said Michael Heinz, member of the Board of Executive Directors of BASF SE and responsible for the Performance Products segment, which includes the Nutrition Health division.

Pronovas active pharmaceutical ingredients are used to treat cardiovascular diseases such as post-myocardial infarction. In nutritional applications, including dietary supplements, there is a strong body of evidence supporting a broad range of positive health benefits through omega-3 fatty acids, for example, in the
3/5 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/09 01:13